ERYP vs. MGTX, SANA, RGNX, TRML, TECX, AUTL, ITOS, DBVT, ATYR, and HUMA
Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include MeiraGTx (MGTX), Sana Biotechnology (SANA), REGENXBIO (RGNX), Tourmaline Bio (TRML), Tectonic Therapeutic (TECX), Autolus Therapeutics (AUTL), iTeos Therapeutics (ITOS), DBV Technologies (DBVT), Atyr PHARMA (ATYR), and Humacyte (HUMA). These companies are all part of the "biological products, except diagnostic" industry.
ERYTECH Pharma vs.
MeiraGTx (NASDAQ:MGTX) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.
MeiraGTx presently has a consensus price target of $24.00, indicating a potential upside of 370.59%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than ERYTECH Pharma.
MeiraGTx received 32 more outperform votes than ERYTECH Pharma when rated by MarketBeat users. Likewise, 71.59% of users gave MeiraGTx an outperform vote while only 57.45% of users gave ERYTECH Pharma an outperform vote.
67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by insiders. Comparatively, 1.9% of ERYTECH Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
MeiraGTx has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500.
In the previous week, MeiraGTx had 8 more articles in the media than ERYTECH Pharma. MarketBeat recorded 8 mentions for MeiraGTx and 0 mentions for ERYTECH Pharma. MeiraGTx's average media sentiment score of 0.26 beat ERYTECH Pharma's score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media.
ERYTECH Pharma has a net margin of 0.00% compared to MeiraGTx's net margin of -633.05%. ERYTECH Pharma's return on equity of 0.00% beat MeiraGTx's return on equity.
ERYTECH Pharma has lower revenue, but higher earnings than MeiraGTx.
Summary
MeiraGTx beats ERYTECH Pharma on 11 of the 16 factors compared between the two stocks.
Get ERYTECH Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ERYTECH Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ERYP) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy ERYP Stock Free ERYP Stock Alerts